feedback

Course Director

David T. Rubin, MD
David T. Rubin, MD

Digestive Diseases Center
University of Chicago Medicine
Chicago, Illinois

Faculty

Jessica R. Allegretti
Jessica R. Allegretti, MD, MPH

Brigham and Women's Hospital
Harvard Medical School
Boston, Massachusetts

Stephen B. Hanauer
Stephen B. Hanauer, MD

Northwestern Feinberg School of Medicine
Chicago, Illinois

Accredited by

American Gastroenterological Association

Activity Details

Credit Types:CME
Credit Amount:1.5 Credits
Release Date:2020-Mar-03
Expiration Date:2021-Mar-02
Estimated Time for Completion:90 minutes
Registration Required:No
Cost:Free of Charge

Activity Description and Educational Objectives

The past decade has brought substantial advances in the management of IBD. Nevertheless, under current therapeutic options, half of patients with moderate to severe ulcerative colitis (UC) or Crohn’s disease (CD) fail to achieve sustained remission. After years of IBD treatment dominated by monoclonal antibodies, we are currently witnessing promising developments of small molecules for UC and CD. Among them, Janus kinase (JAK) inhibitors are a promising new class that have demonstrated efficacy with a favorable safety profile in clinical trials.

Utilizing a mix of didactic presentations and prerecorded patient videos, this activity based on a live symposium will explore current and emerging treatments and guidelines for UC and CD. The faculty panel provides a thorough examination of current and emerging JAK inhibitors, as well as insight into patient-centered, treat-to-target management approaches in IBD.

Upon completion of this activity, participants should be better able to:
  • Examine the burden of illness and unmet needs in patients with inflammatory bowel disease
  • Summarize efficacy and safety data related to current and emerging JAK inhibitors for the treatment of Crohn’s disease (CD) and ulcerative colitis (UC)
  • Treat CD and UC in accordance with current evidence and guidelines, recognizing the role of non–anti-TNF therapies in inducing and maintaining remission in patients with moderate to severe disease
  • Incorporate JAK inhibitors into treatment plans for individual patients with CD or UC, recognizing the importance of achieving therapeutic targets and a patient-centered approach to care

Target Audience

This activity has been designed to meet the educational needs of gastroenterologists and other clinicians involved in the management of patients with inflammatory bowel disease.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the evaluation form and request for credit. There are no prerequisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the evaluation form and the request for credit.

Media: Enduring Material
Release and Expiration Dates: March 3, 2020 - March 2, 2021
Time to Complete: 90 minutes

Faculty and Disclosure / Conflict of Interest Policy

In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 12 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.

Chair
David T. Rubin, MD
Joseph B. Kirsner Professor of Medicine
Chief, Section of Gastroenterology, Hepatology & Nutrition
Co-Director, Digestive Diseases Center
University of Chicago Medicine
Chicago, Illinois

David T. Rubin, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Allergan; AbGenomics; Biomica; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb; Celgene Corporation/Syneos Health; Check-Cap; Dizal Pharmaceutical; Galen US Inc./Atlantic Pharmaceuticals, Inc.; Eli Lilly and Company; Genentech, Inc./F. Hoffmann-La Roche Ltd; Gilead; Glenmark Pharmaceutical Inc., USA; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Mahana Therapeutics Inc.; Narrow River Management; Pfizer Inc.; Prometheus Laboratories Inc.; Reistone Biopharma; Seres Therapeutics; Shire; Takeda Pharmaceuticals U.S.A., Inc.; Target PharmaSolutions, Inc.; and Techlab, Inc.
Grant/Research Support from AbbVie Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd; Janssen Pharmaceuticals, Inc.; Prometheus Laboratories Inc.; Shire; and Takeda Pharmaceuticals U.S.A., Inc.
Stock Shareholder in AbGenomics and Biomica.
Other Financial or Material Support from The American College of Gastroenterology as a member of the Board of Trustees. Is the Co-Founder, CFO of Cornerstones Health, Inc. (non-profit). Is the Co-Founder of GoDuRn, LLC

Faculty
Jessica R. Allegretti, MD, MPH
Director, Clinical Trials, Crohn's and Colitis Center
Division of Gastroenterology, Brigham and Women's Hospital
Assistant Professor of Medicine, Harvard Medical School
Boston, Massachusetts

Jessica R. Allegretti, MD, MPH, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Finch Therapeutics; Iterative Scopes, Inc.; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; and Takeda Pharmaceuticals U.S.A., Inc.
Grant/Research Support from Merck & Co., Inc.

Stephen B. Hanauer, MD
Clifford Joseph Barborka Professor of Medicine
Northwestern Feinberg School of Medicine
Medical Director, Digestive Health Center
Chicago, Illinois

Stephen B. Hanauer, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Allergan; Amgen; Arena Pharmaceuticals, Inc.; Bristol-Myers Squibb; Celltrion; Genentech; Gilead Sciences, Inc.; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Nestle; Novartis Pharmaceuticals Corporation; Pfizer; Progenity, Inc.; Prometheus Laboratories Inc.; Receptos, Inc.; Salix Pharmaceuticals, Inc.; Samsung Bioepis; Seres Therapeutics; Takeda Pharmaceuticals U.S.A., Inc.; UCB; and Vhsquared.
Grant/Research Support from AbbVie Inc.; Allergan; Amgen; Genentech; Gilead Sciences, Inc.; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Prometheus Laboratories Inc.; Receptos, Inc.; Seres Therapeutics; Takeda Pharmaceuticals U.S.A., Inc.
Data Safety Monitoring Board for Arena Pharmaceuticals, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; and Bristol-Myers Squibb.
Speaker for AbbVie Inc.; Janssen Pharmaceuticals, Inc.; and Takeda Pharmaceuticals U.S.A., Inc

Medical Director
Kathryn B. Charalambous, PhD
PVI, PeerView Institute for Medical Education

Kathryn B. Charalambous, PhD, has no financial interests/relationships or affiliations in relation to this activity.

Providership, Credit, and Support


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Gastroenterological Association (AGA) Institute and PVI, PeerView Institute for Medical Education. The AGA Institute is accredited by the ACCME to provide continuing medical education for physicians.

The AGA Institute designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Providership

This CME activity is jointly provided by the American Gastroenterological Association Institute and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by an educational grant from Gilead Sciences, Inc.

The patient perspective for this CME activity was provided in collaboration with the Crohn's & Colitis Foundation.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

About This CME Activity

PVI, PeerView Institute for Medical Education, and the American Gastroenterological Association Institute are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and the American Gastroenterological Association Institute.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2020, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.